Everything Clinical Trials
Designing studies, capturing and monitoring trial data, managing investigator sites and everything in between.
Discoveries driven by genomic data could dramatically increase the number of biomarkers available for use in clinical trials.
When optimizing your study practice, it is vital to evaluate every trial phase in context.
While new guidance has created a much needed sense of urgency to define a risk-based monitoring approach to clinical trials, there is one critical area of monitoring that cannot be ignored.
Nearly 20 years ago Medidata was built around modernizing data capture and management, which ultimately became Rave. Today, we can confidently say we’re so much more than that.
Yesterday we discussed how researchers are trying to incorporate new biomarker data into studies, which can generate a new set of hurdles for clinical development programs. It's clear that overcoming these challenges starts with integration.